Diagnosis and management of glycogen storage disease type IV, including adult polyglucosan body disease: A clinical practice resource
- PMID:36796138
- DOI: 10.1016/j.ymgme.2023.107525
Diagnosis and management of glycogen storage disease type IV, including adult polyglucosan body disease: A clinical practice resource
Abstract
Glycogen storage disease type IV (GSD IV) is an ultra-rare autosomal recessive disorder caused by pathogenic variants in GBE1 which results in reduced or deficient glycogen branching enzyme activity. Consequently, glycogen synthesis is impaired and leads to accumulation of poorly branched glycogen known as polyglucosan. GSD IV is characterized by a remarkable degree of phenotypic heterogeneity with presentations in utero, during infancy, early childhood, adolescence, or middle to late adulthood. The clinical continuum encompasses hepatic, cardiac, muscular, and neurologic manifestations that range in severity. The adult-onset form of GSD IV, referred to as adult polyglucosan body disease (APBD), is a neurodegenerative disease characterized by neurogenic bladder, spastic paraparesis, and peripheral neuropathy. There are currently no consensus guidelines for the diagnosis and management of these patients, resulting in high rates of misdiagnosis, delayed diagnosis, and lack of standardized clinical care. To address this, a group of experts from the United States developed a set of recommendations for the diagnosis and management of all clinical phenotypes of GSD IV, including APBD, to support clinicians and caregivers who provide long-term care for individuals with GSD IV. The educational resource includes practical steps to confirm a GSD IV diagnosis and best practices for medical management, including (a) imaging of the liver, heart, skeletal muscle, brain, and spine, (b) functional and neuromusculoskeletal assessments, (c) laboratory investigations, (d) liver and heart transplantation, and (e) long-term follow-up care. Remaining knowledge gaps are detailed to emphasize areas for improvement and future research.
Keywords: Adult polyglucosan body disease; Andersen disease; Clinical practice guideline; Diagnosis guideline; Glycogen branching enzyme; Glycogen storage disease type IV; Management guideline.
Published by Elsevier Inc.
Similar articles
- Glycogen storage disease type IV without detectable polyglucosan bodies: importance of broad gene panels.Oliwa A, Langlands G, Sarkozy A, Munot P, Stewart W, Phadke R, Topf A, Straub V, Duncan R, Wigley R, Petty R, Longman C, Farrugia ME.Oliwa A, et al.Neuromuscul Disord. 2023 Sep;33(9):98-105. doi: 10.1016/j.nmd.2023.07.004. Epub 2023 Jul 23.Neuromuscul Disord. 2023.PMID:37598009
- A novel mouse model that recapitulates adult-onset glycogenosis type 4.Orhan Akman H, Emmanuele V, Kurt YG, Kurt B, Sheiko T, DiMauro S, Craigen WJ.Orhan Akman H, et al.Hum Mol Genet. 2015 Dec 1;24(23):6801-10. doi: 10.1093/hmg/ddv385. Epub 2015 Sep 18.Hum Mol Genet. 2015.PMID:26385640Free PMC article.
- Neuropathological study of skeletal muscle, heart, liver, and brain in a neonatal form of glycogen storage disease type IV associated with a new mutation in GBE1 gene.Lamperti C, Salani S, Lucchiari S, Bordoni A, Ripolone M, Fagiolari G, Fruguglietti ME, Crugnola V, Colombo C, Cappellini A, Prelle A, Bresolin N, Comi GP, Moggio M.Lamperti C, et al.J Inherit Metab Dis. 2009 Dec;32 Suppl 1:S161-8. doi: 10.1007/s10545-009-1134-8. Epub 2009 Apr 8.J Inherit Metab Dis. 2009.PMID:19357989
- The variable presentations of glycogen storage disease type IV: a review of clinical, enzymatic and molecular studies.Moses SW, Parvari R.Moses SW, et al.Curr Mol Med. 2002 Mar;2(2):177-88. doi: 10.2174/1566524024605815.Curr Mol Med. 2002.PMID:11949934Review.
- Severe neuromuscular forms of glycogen storage disease type IV: Histological, clinical, biochemical, and molecular findings in a large French case series.Lefèvre CR, Collardeau-Frachon S, Streichenberger N, Berenguer-Martin S, Clémenson A, Massardier J, Prieur F, Laurichesse H, Laffargue F, Acquaviva-Bourdain C, Froissart R, Pettazzoni M.Lefèvre CR, et al.J Inherit Metab Dis. 2024 Mar;47(2):255-269. doi: 10.1002/jimd.12692. Epub 2023 Nov 27.J Inherit Metab Dis. 2024.PMID:38012812Review.
Cited by
- Continuous glucose monitoring in patients with inherited metabolic disorders at risk for Hypoglycemia and Nutritional implications.Gugelmo G, Maines E, Boscari F, Lenzini L, Fadini GP, Burlina A, Avogaro A, Vitturi N.Gugelmo G, et al.Rev Endocr Metab Disord. 2024 Oct;25(5):897-910. doi: 10.1007/s11154-024-09903-y. Epub 2024 Oct 1.Rev Endocr Metab Disord. 2024.PMID:39352577Free PMC article.Review.
- Gene therapy for glycogen storage diseases.Koeberl DD, Koch RL, Lim JA, Brooks ED, Arnson BD, Sun B, Kishnani PS.Koeberl DD, et al.J Inherit Metab Dis. 2024 Jan;47(1):93-118. doi: 10.1002/jimd.12654. Epub 2023 Jul 27.J Inherit Metab Dis. 2024.PMID:37421310Free PMC article.Review.
- Metabolic Liver Diseases Presenting as Pediatric Onset Hypoglycemia: A Hepatologist's Primer.Verma S, Sood V, Lal BB, Khanna R, Alam S.Verma S, et al.J Clin Exp Hepatol. 2025 Jan-Feb;15(1):102425. doi: 10.1016/j.jceh.2024.102425. Epub 2024 Oct 11.J Clin Exp Hepatol. 2025.PMID:39553835
- Endocrine involvement in hepatic glycogen storage diseases: pathophysiology and implications for care.Rossi A, Simeoli C, Pivonello R, Salerno M, Rosano C, Brunetti B, Strisciuglio P, Colao A, Parenti G, Melis D, Derks TGJ.Rossi A, et al.Rev Endocr Metab Disord. 2024 Aug;25(4):707-725. doi: 10.1007/s11154-024-09880-2. Epub 2024 Apr 1.Rev Endocr Metab Disord. 2024.PMID:38556561Free PMC article.Review.
- Natural history study of hepatic glycogen storage disease type IV and comparison to Gbe1ys/ys model.Koch RL, Kiely BT, Choi SJ, Jeck WR, Flores LS, Sood V, Alam S, Porta G, LaVecchio K, Soler-Alfonso C, Kishnani PS.Koch RL, et al.JCI Insight. 2024 May 14;9(12):e177722. doi: 10.1172/jci.insight.177722.JCI Insight. 2024.PMID:38912588Free PMC article.
Publication types
MeSH terms
Substances
Supplementary concepts
Related information
LinkOut - more resources
Full Text Sources
Medical